Glaucoma in adults—screening, diagnosis, and management: a review
JD Stein, AP Khawaja, JS Weizer - Jama, 2021 - jamanetwork.com
Importance Glaucoma is the most common cause of irreversible blindness worldwide. Many
patients with glaucoma are asymptomatic early in the disease course. Primary care …
patients with glaucoma are asymptomatic early in the disease course. Primary care …
[HTML][HTML] Updates on the Diagnosis and Management of Glaucoma
IV Wagner, MW Stewart, SK Dorairaj - Mayo Clinic Proceedings …, 2022 - Elsevier
Glaucoma is the leading cause of blindness throughout the world (after cataracts); therefore,
general physicians should be familiar with the diagnosis and management of affected …
general physicians should be familiar with the diagnosis and management of affected …
Primary open-angle glaucoma preferred practice pattern®
SJ Gedde, K Vinod, MM Wright, KW Muir, JT Lind… - Ophthalmology, 2021 - Elsevier
Background Primary open angle glaucoma (POAG) is a chronic, progressive ocular disease
causing loss of the optic nerve rim and retinal nerve fiber layer (RNFL) with associated …
causing loss of the optic nerve rim and retinal nerve fiber layer (RNFL) with associated …
[HTML][HTML] Ab-externo MicroShunt versus trabeculectomy in primary open-angle glaucoma: one-year results from a 2-year randomized, multicenter study
ND Baker, HS Barnebey, MR Moster, MC Stiles… - Ophthalmology, 2021 - Elsevier
Purpose To compare the effectiveness and safety of the MicroShunt versus trabeculectomy
in patients with primary open-angle glaucoma (POAG). Design One-year results from a 2 …
in patients with primary open-angle glaucoma (POAG). Design One-year results from a 2 …
Glaucoma: now and beyond
H Jayaram, M Kolko, DS Friedman, G Gazzard - The Lancet, 2023 - thelancet.com
The glaucomas are a group of conditions leading to irreversible sight loss and characterised
by progressive loss of retinal ganglion cells. Although not always elevated, intraocular …
by progressive loss of retinal ganglion cells. Although not always elevated, intraocular …
The surgical management of glaucoma: A review
R Lim - Clinical & Experimental Ophthalmology, 2022 - Wiley Online Library
After a long period of little change, glaucoma surgery has experienced a dramatic rise in the
number of possible procedures in the last two decades. Glaucoma filtering surgeries with …
number of possible procedures in the last two decades. Glaucoma filtering surgeries with …
Long-term outcomes from the HORIZON randomized trial for a Schlemm's canal microstent in combination cataract and glaucoma surgery
IIK Ahmed, T De Francesco, D Rhee, C McCabe… - Ophthalmology, 2022 - Elsevier
Purpose To present the 5-year results of the HORIZON trial comparing cataract surgery (CS)
combined with an intracanalicular microstent with CS alone. Design Prospective …
combined with an intracanalicular microstent with CS alone. Design Prospective …
Comparing the efficacy of trabeculectomy and XEN gel microstent implantation for the treatment of primary open-angle glaucoma: a retrospective monocentric …
T Theilig, M Rehak, C Busch, C Bormann… - Scientific reports, 2020 - nature.com
The aim of this study was to compare the efficacy and safety profile of XEN microstent
implantation with trabeculectomy (TET) in a comparable group of open-angle glaucoma …
implantation with trabeculectomy (TET) in a comparable group of open-angle glaucoma …
Three-year findings of the HORIZON trial: a Schlemm canal microstent for pressure reduction in primary open-angle glaucoma and cataract
IIK Ahmed, DJ Rhee, J Jones, IP Singh, N Radcliffe… - Ophthalmology, 2021 - Elsevier
Purpose To report 3-year outcomes of the HORIZON study comparing cataract surgery (CS)
with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone. Design Multicenter …
with Hydrus Microstent (Ivantis, Inc) implantation versus CS alone. Design Multicenter …
Intermediate outcomes of a novel standalone ab externo SIBS microshunt with mitomycin C
MB Schlenker, GM Durr, E Michaelov… - American Journal of …, 2020 - Elsevier
Purpose To determine the efficacy, risk factors for failure, and adverse events of a
standalone novel ab externo SIBS microshunt with mitomycin C (MMC) during 1-year follow …
standalone novel ab externo SIBS microshunt with mitomycin C (MMC) during 1-year follow …